Cargando…

Evaluation of an octahydroisochromene scaffold used as a novel SARS 3CL protease inhibitor

An octahydroisochromene scaffold has been introduced into a known SARS 3CL protease inhibitor as a novel hydrophobic core to interact with the S2 pocket of the protease. An alkyl or aryl substituent was also introduced at the 1-position of the octahydroisochromene scaffold and expected to introduce...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshizawa, Shin-ichiro, Hattori, Yasunao, Kobayashi, Kazuya, Akaji, Kenichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127348/
https://www.ncbi.nlm.nih.gov/pubmed/31926775
http://dx.doi.org/10.1016/j.bmc.2019.115273
_version_ 1783516340785512448
author Yoshizawa, Shin-ichiro
Hattori, Yasunao
Kobayashi, Kazuya
Akaji, Kenichi
author_facet Yoshizawa, Shin-ichiro
Hattori, Yasunao
Kobayashi, Kazuya
Akaji, Kenichi
author_sort Yoshizawa, Shin-ichiro
collection PubMed
description An octahydroisochromene scaffold has been introduced into a known SARS 3CL protease inhibitor as a novel hydrophobic core to interact with the S2 pocket of the protease. An alkyl or aryl substituent was also introduced at the 1-position of the octahydroisochromene scaffold and expected to introduce additional interactions with the protease. Sharpless–Katsuki asymmetric epoxidation and Sharpless asymmetric dihydroxylation were employed to construct the octahydroisochromene scaffold. The introductions of the P1 site His-al and the substituent at 1-position was achieved using successive reductive amination reactions. Our initial evaluations of the diastereo-isomeric mixtures (16a–d) revealed that the octahydroisochromene moiety functions as a core hydrophobic scaffold for the S2 pocket of the protease and the substituent at the 1-position may form additional interactions with the protease. The inhibitory activities of the diastereoisomerically-pure inhibitors (3a–d) strongly suggest that a specific stereo-isomer of the octahydroisochromene scaffold, (1S, 3S) 3b, directs the P1 site imidazole, the warhead aldehyde, and substituent at the 1-position of the fused ring to their appropriate pockets in the protease.
format Online
Article
Text
id pubmed-7127348
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-71273482020-04-08 Evaluation of an octahydroisochromene scaffold used as a novel SARS 3CL protease inhibitor Yoshizawa, Shin-ichiro Hattori, Yasunao Kobayashi, Kazuya Akaji, Kenichi Bioorg Med Chem Article An octahydroisochromene scaffold has been introduced into a known SARS 3CL protease inhibitor as a novel hydrophobic core to interact with the S2 pocket of the protease. An alkyl or aryl substituent was also introduced at the 1-position of the octahydroisochromene scaffold and expected to introduce additional interactions with the protease. Sharpless–Katsuki asymmetric epoxidation and Sharpless asymmetric dihydroxylation were employed to construct the octahydroisochromene scaffold. The introductions of the P1 site His-al and the substituent at 1-position was achieved using successive reductive amination reactions. Our initial evaluations of the diastereo-isomeric mixtures (16a–d) revealed that the octahydroisochromene moiety functions as a core hydrophobic scaffold for the S2 pocket of the protease and the substituent at the 1-position may form additional interactions with the protease. The inhibitory activities of the diastereoisomerically-pure inhibitors (3a–d) strongly suggest that a specific stereo-isomer of the octahydroisochromene scaffold, (1S, 3S) 3b, directs the P1 site imidazole, the warhead aldehyde, and substituent at the 1-position of the fused ring to their appropriate pockets in the protease. Elsevier Ltd. 2020-02-15 2019-12-30 /pmc/articles/PMC7127348/ /pubmed/31926775 http://dx.doi.org/10.1016/j.bmc.2019.115273 Text en © 2019 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Yoshizawa, Shin-ichiro
Hattori, Yasunao
Kobayashi, Kazuya
Akaji, Kenichi
Evaluation of an octahydroisochromene scaffold used as a novel SARS 3CL protease inhibitor
title Evaluation of an octahydroisochromene scaffold used as a novel SARS 3CL protease inhibitor
title_full Evaluation of an octahydroisochromene scaffold used as a novel SARS 3CL protease inhibitor
title_fullStr Evaluation of an octahydroisochromene scaffold used as a novel SARS 3CL protease inhibitor
title_full_unstemmed Evaluation of an octahydroisochromene scaffold used as a novel SARS 3CL protease inhibitor
title_short Evaluation of an octahydroisochromene scaffold used as a novel SARS 3CL protease inhibitor
title_sort evaluation of an octahydroisochromene scaffold used as a novel sars 3cl protease inhibitor
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127348/
https://www.ncbi.nlm.nih.gov/pubmed/31926775
http://dx.doi.org/10.1016/j.bmc.2019.115273
work_keys_str_mv AT yoshizawashinichiro evaluationofanoctahydroisochromenescaffoldusedasanovelsars3clproteaseinhibitor
AT hattoriyasunao evaluationofanoctahydroisochromenescaffoldusedasanovelsars3clproteaseinhibitor
AT kobayashikazuya evaluationofanoctahydroisochromenescaffoldusedasanovelsars3clproteaseinhibitor
AT akajikenichi evaluationofanoctahydroisochromenescaffoldusedasanovelsars3clproteaseinhibitor